Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non‐Hodgkin's lymphoma

Abstract

These data suggest that infused CD34+ cell count is predictive of kinetics of lymphocyte recovery after ASCT and is an independent prognostic factor for OS and EFS after ASCT in patients with NHL.

Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo

“…10, 12, 15, 16, 89 Re-infusion of high doses of CD34 + cells is associated with fast platelet and neutrophil engraftment, leading to a significant cost sparing 25, 26, 51, 90, 91, 92, 93, 94 and increased survival rates. 52, 95, 96, 97, 98, 99, 100 GITMO-WG selected two conceptual criteria to identify proven PM and/or PPM: (I) peak of CD34 + cells in PB and (II) harvested CD34 + cells.…”

Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process

“…61 Higher CD34+ cell doses, that is, more than 8 ¥ 10 6 /kg/ body weight do not support a better engraftment; however, in some settings, such as non-Hodgkin's lymphomas, better event-free and overall survival are reported. 62 In contrast, in the acute myeloid leukemia setting, a CD34 dose higher than 7 ¥ 10 6 /kg/body weight was associated with a worse disease-free survival. 63…”

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

“…8 CD34 þ cell dose and outcome Several studies have evaluated the relation of CD34 þ cell dose and to patient outcome after auto-SCT. [16][17][18][19][20][21][22][23][24][25][26][27] These studies are summarised in Table 2. The general impression is that better blood stem-cell mobilization or a higher CD34 þ cell dose is associated with superior-outcome post transplant.…”